CANDEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.43 USD | +6.28% |
|
+17.77% | +337.41% |
| Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
| Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 189M |
|---|---|---|---|---|---|
| Net income 2024 * | -41M | Net income 2025 * | - | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-7.07
x | P/E ratio 2025 * |
-
| Employees | 42 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +6.28% | ||
| 1 week | +17.77% | ||
| Current month | +306.96% | ||
| 1 month | +323.03% | ||
| 3 months | +410.32% | ||
| 6 months | +622.47% | ||
| Current year | +337.41% |
1 week
5.10
6.81
1 month
1.4511.40
Current year
1.1611.40
1 year
0.6611.40
3 years
0.6614.78
5 years
0.6614.78
10 years
0.6614.78
| Managers | Title | Age | Since |
|---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 20-08-31 |
| Founder | 66 | 01-12-31 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 22-08-07 |
Edward Benz
BRD | Director/Board Member | 78 | 17-08-31 |
Paul Manning
CHM | Chairman | 68 | 18-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 6.43 | +6.28% | 750,648 |
| 24-04-24 | 6.05 | +2.37% | 672,175 |
| 24-04-23 | 5.91 | +6.68% | 462,336 |
| 24-04-22 | 5.54 | +7.16% | 581,998 |
| 24-04-19 | 5.17 | -5.31% | 568,360 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
6.43
USD
Average target price
11
USD
Spread / Average Target
+71.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +337.41% | 189M | |
| +1.12% | 42.59B | |
| +6.77% | 40.65B | |
| +45.26% | 40.57B | |
| -11.96% | 26.77B | |
| +6.01% | 24.81B | |
| -24.92% | 18.17B | |
| -3.63% | 11.7B | |
| +27.16% | 12.05B | |
| +7.30% | 11.1B |
- Stock Market
- Equities
- CADL Stock
